Stocks
Novartis Financial Statements (NVS) |
||||||||||
| Novartissmart-lab.ru | % | 2023Q1 | 2023Q2 | 2023Q3 | 2023Q4 | 2024Q1 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 31.03.2023 | 30.06.2023 | 30.09.2023 | 31.01.2024 | 31.03.2024 | 31.03.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 13 208 | 13 936 | 12 092 | 11 776 | 11 829 | 49 633 | |||
| Operating Income, bln rub | 2 856 | 2 920 | 1 762 | 2 582 | 3 629 | 10 893 | ||||
| EBITDA, bln rub | ? | 4 947 | 4 818 | 4 885 | 4 182 | 4 943 | 18 828 | |||
| Net profit, bln rub | ? | 2 293 | 2 316 | 1 761 | 8 480 | 2 688 | 15 245 | |||
| OCF, bln rub | ? | 2 957 | 3 576 | 5 378 | 2 547 | 2 265 | 13 766 | |||
| CAPEX, bln rub | ? | 470.0 | 996.0 | 683.0 | 783.0 | 1 156 | 3 618 | |||
| FCF, bln rub | ? | 2 487 | 2 580 | 4 695 | 1 764 | 1 109 | 10 148 | |||
| Dividend payout, bln rub | 7 255 | 0.000 | 0.000 | 0.000 | 5 207 | 5 207 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| Dividend payout ratio, % | 316.4% | 0.00% | 0.00% | 0.00% | 193.7% | 34.2% | ||||
| OPEX, bln rub | 6 421 | 6 675 | 7 213 | 6 172 | 5 070 | 25 130 | ||||
| Cost of production, bln rub | 3 931 | 4 341 | 3 117 | 3 022 | 3 130 | 13 610 | ||||
| R&D, bln rub | 2 794 | 2 526 | 3 925 | 2 567 | 2 230 | 11 248 | ||||
| Interest expenses, bln rub | 211.0 | 224.0 | 222.0 | 217.0 | 221.0 | 884.0 | ||||
| Assets, bln rub | 112 241 | 110 979 | 112 697 | 99 945 | 94 334 | 94 334 | ||||
| Net Assets, bln rub | ? | 52 059 | 51 847 | 38 164 | 46 667 | 39 675 | 39 675 | |||
| Debt, bln rub | 29 204 | 28 340 | 25 189 | 26 348 | 27 284 | 27 284 | ||||
| Cash, bln rub | 12 260 | 11 174 | 12 695 | 13 962 | 9 694 | 9 694 | ||||
| Net debt, bln rub | 16 944 | 17 166 | 12 494 | 12 386 | 17 590 | 17 590 | ||||
| Ordinary share price, rub | 87.1 | 95.5 | 96.4 | 101.0 | 96.7 | 84.0 | ||||
| Number of ordinary shares, mln | 2 110 | 2 083 | 2 062 | 2 050 | 2 044 | 2 044 | ||||
| Market cap, bln rub | 183 697 | 198 906 | 198 756 | 206 989 | 197 716 | 171 696 | ||||
| EV, bln rub | ? | 200 641 | 216 072 | 211 250 | 219 375 | 215 306 | 189 286 | |||
| Book value, bln rub | -7 873 | -5 678 | -11 670 | -3 553 | -9 660 | -9 660 | ||||
| EPS, rub | ? | 1.09 | 1.11 | 0.85 | 4.14 | 1.32 | 7.46 | |||
| FCF/share, rub | 1.18 | 1.24 | 2.28 | 0.86 | 0.54 | 4.96 | ||||
| BV/share, rub | -3.73 | -2.73 | -5.66 | -1.73 | -4.73 | -4.73 | ||||
| EBITDA margin, % | ? | 37.5% | 34.6% | 40.4% | 35.5% | 41.8% | 37.9% | |||
| Net margin, % | ? | 17.4% | 16.6% | 14.6% | 72.0% | 22.7% | 30.7% | |||
| FCF yield, % | ? | 7.22% | 6.37% | 6.65% | 5.57% | 5.13% | 5.91% | |||
| ROE, % | ? | 13.5% | 14.8% | 20.5% | 31.8% | 38.4% | 38.4% | |||
| ROA, % | ? | 6.26% | 6.89% | 6.95% | 14.9% | 16.2% | 16.2% | |||
| P/E | ? | 26.1 | 26.0 | 25.4 | 13.9 | 13.0 | 11.3 | |||
| P/FCF | 13.9 | 15.7 | 15.0 | 18.0 | 19.5 | 16.9 | ||||
| P/S | ? | 3.52 | 3.75 | 3.80 | 4.06 | 3.98 | 3.46 | |||
| P/BV | ? | -23.3 | -35.0 | -17.0 | -58.3 | -20.5 | -17.8 | |||
| EV/EBITDA | ? | 11.8 | 12.1 | 11.4 | 11.6 | 11.4 | 10.1 | |||
| Debt/EBITDA | 0.99 | 0.96 | 0.67 | 0.66 | 0.93 | 0.93 | ||||
| R&D/CAPEX, % | 594.5% | 253.6% | 574.7% | 327.8% | 192.9% | 310.9% | ||||
| CAPEX/Revenue, % | 3.56% | 7.15% | 5.65% | 6.65% | 9.77% | 7.29% | ||||
| Novartis shareholders | ||||||||||
